-
公开(公告)号：US11492417B2
公开(公告)日：2022-11-08
申请号：US16579321
申请日：2019-09-23
Applicant: AMGEN INC.
Inventor： Hailing Hsu , Ming Zhang , Gunasekaran Kannan , Frederick Jacobsen , Wayne Tsuji
IPC: C07K16/28 , C07K16/46 , A61P37/06 , A61P19/02 , A61P29/02 , A61K39/395 , C07K16/18 , C07K16/24 , A61K39/00
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
-
公开(公告)号：US20210206881A1
公开(公告)日：2021-07-08
申请号：US16579321
申请日：2019-09-23
Applicant: AMGEN INC.
Inventor： Hailing Hsu , Ming Zhang , Gunasekaran Kannan , Frederick Jacobsen , Wayne Tsuji
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
-
公开(公告)号：US10851144B2
公开(公告)日：2020-12-01
申请号：US15565376
申请日：2016-05-04
Applicant: AMGEN INC.
Inventor： Eric Alan Butz , Christy Ann Thomson , Marc Alain Gavin , Ian Nevin Foltz , Dong Xia , Dina N. Alcorn , Ai Ching Lim , Randal Robert Ketchum , Kathy Manchulenko , Laura Sekirov , Kelly Ann Berry , Cyr Clovis Chua De Imus , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Li Li
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US10829535B2
公开(公告)日：2020-11-10
申请号：US15901705
申请日：2018-02-21
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Gunasekaran Kannan , Li Li , Joshua T. Pearson , Margaret Karow
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
Patent Agency Ranking
公开(公告)号：US10465009B2
公开(公告)日：2019-11-05
申请号：US14649469
申请日：2013-12-05
Applicant: Amgen Inc.
Inventor： Richard J. Armitage , Michelle Blake , William C. Fanslow, III , Jason Charles O'Neill , Gunasekaran Kannan , Jiangchun Xu , Mark Edward Tometsko , Zhulun Wang , Athena Sudom
Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
-
公开(公告)号：US10233237B2
公开(公告)日：2019-03-19
申请号：US14086190
申请日：2013-11-21
Applicant: AMGEN INC.
Inventor： Gunasekaran Kannan , Monica Florio , Zhi Liu , Wei Yan
Abstract: The present application is directed to heterodimeric antibodies and methods of use.
-
公开(公告)号：US10093711B2
公开(公告)日：2018-10-09
申请号：US15371131
申请日：2016-12-06
Applicant: Amgen Inc.
Inventor： Gunasekaran Kannan
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US09862752B2
公开(公告)日：2018-01-09
申请号：US14908459
申请日：2014-07-31
Applicant: Amgen Inc.
Inventor： Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Marissa Mock , Kenneth Walker
IPC: C07K14/00 , C07K14/475
CPC classification number: C07K14/475 , C07K2319/30
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US20140378665A1
公开(公告)日：2014-12-25
申请号：US14374885
申请日：2013-01-28
Applicant: AMGEN INC.
Inventor： Yumei Xiong , Yi Zhang , Jackie Zeqi Sheng , Agnes Eva Hamburger , Murielle Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Kenneth W. Walker , Bryan Lemon
IPC: C07K14/475
CPC classification number: C07K14/475 , A61K39/0005 , A61K2039/6056 , C07K2319/30
Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Abstract translation: 提供GDF15多肽，包含GDF15的构建体及其突变体。 在各种实施方案中，GDF15多肽，包含GDF15的构建体及其突变体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.036 seconds)
